Primary lymphoma of bone - A retrospective study. Experience at the Northern Israel Oncology Center (1979-2000)

M. E. Stein, A. Kuten, E. Gez, K. E. Rosenblatt, K. Drumea, M. Ben-Shachar, J. Zidan, N. Haim, R. Epelbaum

Research output: Contribution to journalArticlepeer-review

41 Scopus citations


Objective: This retrospective study describes our experience with the diagnosis, treatment, results and long-term follow-up of primary bone lymphoma (PBL). Patients and Methods: Nineteen patients diagnosed with PBL were reviewed. Seven patients presented with stage IE disease, four with stage IIE (regional lymphadenopathy), and eight with stage IV disease (disseminated bone involvement). Only one stage IV patient exhibited 'B' symptoms. The majority (72%) demonstrated diffuse, large cell, B-type lymphoma. All patients were treated with adriamycin-based chemotherapy and consolidation radiotherapy to the primary site (8 patients: early PBL) or the most bulky area (3 patients: stage IV PBL). Results: Ten stage IE/IIE patients are alive with no evidence of disease (NED) and only one died due to metastatic secondary lung cancer while with NED from his PBL. Eight stage IV patients are alive with NED. Median follow-up for all living patients: 77 months. Side effects were mild and did not necessitate delay in treatment. Conclusions: Our departmental policy of treating PBL patients with an anthracycline-based regimen and involved field radiotherapy proved to be successful in achieving excellent long-term, disease-free survival. Phase III randomized, controlled, clinical trials will determine the true role of consolidation radiotherapy in PBL, when considering severe late side effects, including radiation-induced bone tumors.

Original languageEnglish
Pages (from-to)322-327
Number of pages6
Issue number4
StatePublished - 2003
Externally publishedYes


  • Chemo-radiotherapy regimes
  • Primary bone lymphoma
  • Prolonged survival


Dive into the research topics of 'Primary lymphoma of bone - A retrospective study. Experience at the Northern Israel Oncology Center (1979-2000)'. Together they form a unique fingerprint.

Cite this